Also listed on Plurogen Therapeutics, LLC, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Feb 19, 2028 · High confidence
20-year base term ends Feb 19, 2028
Feb 19, 2008
Feb 19, 2028
Feb 6, 2018
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 2 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 19, 2008, when application 12/033,692, the earliest non-provisional in its chain, was filed (this one was filed Feb 16, 2017) | Feb 19, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,283,278, US 9,603,966) | resolves to Feb 19, 2028, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Feb 19, 2028 | High confidence |
This family
| Application 12/033,692 | Abandoned not computed | not computed |
| US 8,871,248 | In force Feb 2028 | Feb 2028 |
| US 9,283,278 | In force Feb 2028 | Feb 2028 |
| US 9,603,966 | In force Feb 2028 | Feb 2028 |
| US 9,884,136 | this patent Feb 2028 | Feb 2028 |
| Application 15/867,295 | Abandoned not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 18, 2017 Reel 43333, frame 141 | Rodeheaver, George; Katz, Adam | Plurogen Therapeutics, Inc. | Assignment of Assignor's Interest |
| Mar 20, 2018 Reel 45657, frame 292 | Plurogen Therapeutics, Inc. | Plurogen Therapeutics, LLC | Quitclaim/Transfer |
| Oct 21, 2021 Reel 57927, frame 91 | Medline Industries, LP | Wilmington Trust, National Association | Security Interest |
| Oct 21, 2021 Reel 58040, frame 1 | Medline Industries, LP | Bank Of America, N.a. | Security Interest |
| Mar 3, 2022 Reel 59162, frame 143 | Plurogen Therapeutics, LLC | Medline Industries, LP | Assignment of Assignor's Interest |
| Jun 20, 2025 Reel 71672, frame 100 | Medline Industries, LP | Wilmington Trust, National Association, as Notes Collateral Agent | Patent Security Agreement |
| May 28, 2026 Reel 75643, frame 462 | Medline Industries, LP | Wilmington Trust, National Association, as Notes Collateral Agent | Patent Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 9,283,278, US 9,603,966, ends no earlier than this term, so it caps nothing.